B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $29 to $30.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.